Literature DB >> 9186665

Clinical relevance of Fc gamma receptor polymorphisms.

A Rascu1, R Repp, N A Westerdaal, J R Kalden, J G van de Winkel.   

Abstract

Human IgG receptors are very heterogeneous and we currently distinguish three Fc gamma receptor classes specifying at least 12 receptor isoforms. On top of this complexity, Fc gamma R are further found to differ between different individuals. Polymorphisms have been identified for all three Fc gamma R classes. The best-studied ones represent allelic variation of Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16). The Fc gamma RIIa polymorphism is now considered to be a heritable risk factor for autoimmune and infectious diseases, and support for a relevant role of the IIIb polymorphism has also been obtained. A detailed analysis of the exact contribution of each of these Fc gamma R polymorphisms in relation to previously implicated risk factors should unravel the pathophysiological importance of Fc gamma R polymorphisms in the near future.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9186665     DOI： 10.1111/j.1749-6632.1997.tb52070.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  28 in total

1.  Augmentation of pulmonary host defense against Pseudomonas by FcgammaRIIA cDNA transfer to the respiratory epithelium.

Authors:  S Worgall; P Bezdicek; M K Kim; J G Park; R Singh; M Christofidou-Solomidou; A Prince; I Kovesdi; A D Schreiber; R G Crystal
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

2.  Concurrent and independent binding of Fcgamma receptors IIa and IIIb to surface-bound IgG.

Authors:  T E Williams; S Nagarajan; P Selvaraj; C Zhu
Journal:  Biophys J       Date:  2000-10       Impact factor: 4.033

3.  Concurrent binding to multiple ligands: kinetic rates of CD16b for membrane-bound IgG1 and IgG2.

Authors:  T E Williams; P Selvaraj; C Zhu
Journal:  Biophys J       Date:  2000-10       Impact factor: 4.033

4.  Trial Watch: Monoclonal antibodies in cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Jessica Zucman-Rossi; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

5.  Distribution of the FcgammaRIIIa 176 F/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore.

Authors:  K T Chong; W F Ho; S H Koo; Peter Thompson; Edmund J D Lee
Journal:  Br J Clin Pharmacol       Date:  2006-09-19       Impact factor: 4.335

Review 6.  Antibodies as carrier proteins.

Authors:  B N Rehlaender; M J Cho
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

Review 7.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

8.  Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms.

Authors:  K Manger; R Repp; M Jansen; M Geisselbrecht; R Wassmuth; N A C Westerdaal; A Pfahlberg; B Manger; J R Kalden; J G J van de Winkel
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

Review 9.  Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

Authors:  Mohammad Tabrizi; Gadi Gazit Bornstein; Hamza Suria
Journal:  AAPS J       Date:  2009-11-19       Impact factor: 4.009

10.  FcgammaRIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan.

Authors:  Amre Nasr; Nnaemeka C Iriemenam; Hayder A Giha; Halima A Balogun; Robin F Anders; Marita Troye-Blomberg; Gehad ElGhazali; Klavs Berzins
Journal:  Malar J       Date:  2009-03-13       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.